Alanine ( DrugBank: Alanine )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	1
13	多発性硬化症／視神経脊髄炎	1
298	遺伝性膵炎	1
299	嚢胞性線維症	1

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-000577-29-DE (EUCTR)	27/04/2007	12/10/2006	Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Subjects	A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Subjects Receiving Optimized Treatments with Parkinson Medicinal Products who Continue toExperience Persistent Motor Fluctuations	Treatment of levodopa-responsive Parkinson's subjects with severe motor fluctuations. MedDRA version: 14.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: DUODOPA®Intestinal Gel INN or Proposed INN: Levodopa Other descriptive name: 3-(3,4-Dihydroxyphenyl)-L-alanine; L-3-(3,4-Dihydroxyphenyl)alanine; L-DOPA INN or Proposed INN: Carbidopa Monohydrate Other descriptive name: (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate Trade Name: Sinemet®25-100 INN or Proposed INN: Levodopa Other descriptive name: 3-(3,4-Dihydroxyphenyl)-L-alanine; L-3-(3,4-Dihydroxyphenyl)alanine; L-DOPA INN or Proposed INN: Carbidopa Monohydrate Other descriptive name: (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate	Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)	NULL	Not Recruiting			Female: yes Male: yes	31		United States;Germany

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03418376 (ClinicalTrials.gov)	February 1, 2017	9/1/2018	Carnosine Loading and Periodized Training in MS and HC	The Impact of Carnosine Loading and Rehabilitation Therapy on Exercise Capacity in Multiple Sclerosis.	Multiple Sclerosis;Exercise Therapy;Dietary Supplement	Dietary Supplement: Beta-alanine supplementation;Other: Exercise intervention	Hasselt University	NULL	Completed	18 Years	75 Years	All	45	N/A	Belgium

298. 遺伝性膵炎

臨床試験数 : 95 / 薬物数 : 148 - (DrugBank : 51) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01259544 (ClinicalTrials.gov)	January 2009	12/12/2010	BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency		Chronic Pancreatitis;Healthy Volunteers	Drug: benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)	Meridian Bioscience, Inc.	Virginia Commonwealth University;Asian Institute of Gastroenterology, Hyderabad, India	Completed	18 Years	N/A	All	33	Phase 2	India

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01051999 (ClinicalTrials.gov)	February 2010	15/1/2010	Glutamine Supplementation in Cystic Fibrosis	Glutamine Supplementation and Immunity in Adults With Cystic Fibrosis	Cystic Fibrosis;Immune Function	Dietary Supplement: Glutamine;Dietary Supplement: L-alanine	Emory University	Emmaus Medical, Inc.	Completed	18 Years	N/A	Both	17	Phase 2	United States